Wrong drug units
The #1 cause of chemotherapy denials — a unit mismatch on a high-cost drug is denied or clawed back
Our oncology billing services are built for that reality. We get every drug unit, every NDC, every wastage modifier, and every infusion sequence exactly right, keep every authorization active before treatment begins, and recover the underpayments that quietly erode your already-thin margins — so the revenue you earn actually reaches your account.
Get a free oncology billing audit. We'll review your recent chemotherapy and drug claims and show you, in writing, where revenue is at risk — unit errors, wastage gaps, ASP underpayments, expired authorizations — and exactly how much we can help you recover. No cost, no obligation, findings yours to keep.
The #1 cause of chemotherapy denials — a unit mismatch on a high-cost drug is denied or clawed back
Since 2023, single-dose vial claims without one are returned unprocessable — and payment is held
A high-cost drug administered without active approval is an automatic denial on a drug you already bought
Billing the wrong initial, sequential, or hydration code underpays multi-drug regimens
Drug prices rise faster than quarterly ASP updates, so payments quietly fall below your acquisition cost
The 2026 radiation restructure means outdated delivery codes now deny outright
Mixing routine-care and research charges creates serious audit and compliance exposure
A general biller can process an office visit. Oncology can bankrupt them, because everything about it operates at a scale and a risk level no other specialty approaches.
Cancer drugs are among the most expensive treatments in medicine, and your practice buys them before it bills them. That flips billing from a back-office task into a financial survival function — a single denied immunotherapy claim can wipe out the margin from dozens of clean ones.
Medicare reimburses most physician-administered drugs at a small percentage over the average sales price, and when acquisition costs climb faster than those quarterly price updates, your margin shrinks — or disappears. There's no room to also lose money to coding errors and underpayments.
Mandatory wastage modifiers on every single-dose vial. Strict infusion sequencing hierarchy. Exact start-and-stop time documentation. NDC reporting on every drug. Precise unit calculations. One of the heaviest prior-authorization burdens in medicine. And in 2026, a major restructure of radiation oncology codes on top of it all.
Behind every claim is a cancer patient. When billing fails, prior authorizations lapse and treatment gets delayed — and in oncology, delayed treatment is not a minor inconvenience. Clean billing keeps cancer care moving and protects patients from surprise bills at the worst moment of their lives. That's why oncology billing has to be as precise as the medicine itself.
The losses in oncology aren't small and occasional — they're large and constant, and they come from four places at once.
J-codes are priced per specific unit, and units must be calculated against the vial size, not just the dose ordered. A single wrong unit count or a missing or incorrect NDC on a high-cost drug means an immediate denial or clawback worth thousands.
Single-dose vials rarely divide evenly into a patient's dose, and the discarded portion is billable — but only with the JW modifier, correctly documented; when the full vial is used, the JZ modifier is required. Miss either and the claim is returned unprocessable. Apply JW without documentation and you invite a recoupment audit.
Because drug prices update on a different schedule than reimbursement, payers frequently pay below your true cost without anyone noticing — a quiet, compounding loss that only surfaces when every payment is compared against acquisition cost and contract, claim by claim.
With authorization required for nearly every chemotherapy regimen, immunotherapy, targeted agent, and advanced radiation technique, a single lapsed or missing approval turns a drug you already purchased into an unrecoverable write-off.
We don't offer a generic package with an oncology label. Every service below is built around how cancer practices actually earn — and risk — revenue.
We code every chemotherapy administration to the correct infusion hierarchy — chemotherapy first, therapeutic infusions second, hydration last — with only one initial code per IV access site, precise start-and-stop times on every time-based service, and correct initial, sequential, and concurrent coding so multi-drug regimens pay in full.
For every drug administered under buy-and-bill, we confirm the correct J-code, calculate units against the vial size, attach the accurate 11-digit NDC, and verify the whole claim before it goes out — because on drugs this expensive, a single unit or NDC error is a five-figure problem.
We connect your infusion record to the claim before submission, applying the JW modifier with documented wastage or the JZ modifier for zero waste on every single-dose vial — capturing the reimbursement you're owed while keeping your documentation audit-proof, never auto-applying a modifier that can't be defended.
Oncology carries one of the highest prior-authorization burdens in medicine. Our dedicated team secures approvals for chemotherapy, immunotherapy, targeted agents, biologics, and advanced radiation before treatment begins, and tracks every authorization against its expiration throughout the course of care — so no drug you've purchased goes unpaid.
We code every phase of radiation care — treatment planning, simulation, physics services, treatment delivery, image guidance, and weekly treatment management — and we've fully implemented the 2026 radiation restructure that consolidated delivery codes and rebundled image guidance, so your claims reflect current rules instead of denying on deleted codes.
From established immunotherapy agents to CAR-T cell therapy and the biosimilars entering the code set every quarter, we stay current on new J-codes and HCPCS updates and support the clinical documentation these emerging, high-cost therapies require — including for off-label use.
We benchmark every drug payment against the current ASP and your contracted rates on every remittance, flag the underpayments that quietly drain oncology margins, and pursue recovery before the filing window closes. In a specialty compressed by drug-cost inflation, this alone protects serious revenue.
We code the full oncology diagnosis picture correctly — active malignancy codes, the treatment-encounter Z-codes for chemotherapy and radiation, and personal-history codes for follow-up — with the staging, laterality, and tumor specificity payers now demand to establish medical necessity.
We cleanly separate routine care from research charges so payers are billed only for covered services — protecting your practice from the audit exposure that mixed clinical-trial billing creates.
For biopsies, tumor excisions, and port placements, we handle the surgical coding, global periods, and modifier logic so these services are captured accurately alongside your medical and radiation oncology billing.
Our denial management team works every high-value denial to its root cause — units, wastage, sequencing, authorization, medical necessity — and appeals aggressively, because in oncology a single overturned denial can be worth more than a month of routine claims.
We handle credentialing and enrollment for your oncologists and advanced-practice providers across every payer, starting at hire — so no provider is treating patients they can't yet bill for. Reliable oncology credentialing keeps revenue flowing from day one.
We verify all coverages up front, clarify patient financial responsibility before treatment, and deliver monthly reporting on clean-claim rate, denial rate, drug-reimbursement variance, and days in A/R — so you always know exactly where your practice stands.
Correct units, NDCs, wastage modifiers, and sequencing on every drug and infusion, so your most valuable claims pay the first time.
A dedicated team keeps every chemotherapy, immunotherapy, and radiation approval active before treatment starts — so a drug you bought never becomes a write-off.
We track every drug payment against ASP and contract and recover what you're owed, protecting the thin margins that drug inflation keeps compressing.
Oncology is heavily scrutinized. Precise documentation and compliant wastage and coding keep your denial rate low and your practice audit-ready.
Verified coverage and clear financial navigation mean fewer surprise bills for cancer patients already carrying enough — which protects both your revenue and your reputation.
Whether you're an independent oncologist protecting razor-thin drug margins or a multi-site cancer center coordinating medical, radiation, and surgical oncology, we build around how your practice actually operates — and protect your revenue at every step.
Chemotherapy administration, J-code and NDC precision, JW/JZ compliance, buy-and-bill, ASP tracking, the radiation restructure — this is what we do every day, and on claims this large, that expertise pays for itself immediately.
In oncology, billing isn't back-office paperwork — it's the difference between financial stability and absorbing five-figure losses. We approach every claim that way.
The free audit shows you, in writing, the revenue we can protect and recover — so you decide with real numbers, not promises.
Transparent pricing, honest reporting, and no long-term contract locking you in. If we're not improving your collections within 90 days, you're free to leave.
Our incentives are tied to your revenue, so we're driven to capture and protect every dollar on every high-value claim.
A four-stage protection path moves your practice from claim exposure to measurable control without interrupting treatment.
Tell us about your practice — your drug mix, whether you run medical, radiation, or both, your payer mix. A five-minute form, confirmed within one business day.
Within about a week, you'll get a clear picture of where revenue is at risk — unit errors, wastage gaps, ASP underpayments, expired authorizations — and how much we can recover and protect. Yours to keep.
We work inside your existing system, so nothing changes about your clinic, your infusion suite, or your radiation workflow. Most practices are fully live in two to three weeks, with no gap in claims.
Every month, you see protected margins, fewer denials, active authorizations, and recovered underpayments.
Chemotherapy administration follows a strict hierarchy and time-based rules: chemotherapy is billed first, therapeutic infusions second, and hydration last, with only one "initial" code per IV access site and exact start-and-stop times documented on every time-based service. Missing time documentation forfeits add-on reimbursement, and billing a second initial code without a separate IV site is denied. We sequence every multi-drug regimen correctly so it pays in full.
Both report drug wastage on single-dose vials, and since October 2023 one of them is mandatory on every covered single-dose vial claim — without it, the claim is returned unprocessable. JW reports the discarded portion when part of a vial is thrown away and must be supported by documentation; JZ attests that the entire vial was administered with no waste. Multi-dose vial wastage is not billable. We apply the right modifier with documentation that holds up under audit.
Under buy-and-bill, your practice purchases high-cost chemotherapy and biologic drugs directly and then bills the payer for the drug plus administration, typically at a small percentage over the average sales price. The risk is that you've already spent the money before you bill a cent — so a denial for a wrong unit, missing NDC, or lapsed authorization means a five-figure loss on a drug you've already bought. That's why unit accuracy, NDC reporting, and active authorizations matter so much, and it's exactly what we protect.
The leading causes are drug unit mismatches, missing or incorrect NDCs, absent or expired prior authorizations, missing wastage modifiers, infusion sequencing errors, and diagnosis codes that don't support medical necessity. Because oncology claims are so high-value, each denial is expensive — which is why our denial management and prior authorization work focuses on preventing them before submission and appealing aggressively when they occur.
Yes. We code the full radiation oncology cycle — planning, simulation, physics, delivery, image guidance, and weekly management — under the 2026 restructure, and we cleanly separate routine care from research charges for practices running clinical trials, protecting you from audit exposure.
No. We work inside your existing EHR and practice-management system, so nothing changes about your clinic, infusion suite, or radiation workflow. Most practices transition in two to three weeks with no interruption to claims, and start seeing results within the first billing cycle.
Our pricing is transparent and performance-based — we do well when you get paid. The free audit shows you the revenue we can protect and recover, so you can weigh the cost against the value before you commit. On oncology's high-value claims, the revenue we protect typically far outweighs the cost of the service.
Your team delivers some of the most demanding, most important care in all of medicine — the chemotherapy, the immunotherapy, the radiation that gives patients more time and more life. You shouldn't lose a cent of that hard-earned, high-cost revenue to a wrong drug unit, a missing wastage modifier, or a lapsed authorization on a drug you already bought. Our oncology billing services make sure every claim is billed precisely, paid fully, and protected from the errors and underpayments that hit cancer practices hardest — while keeping treatment moving and surprise bills off your patients' statements.
Start with the free audit. See the number. Then decide.Share a few details about your practice. The written findings and recovery estimate are yours to keep.